Hot off the press! The 2Q10 OnBioVC Trend Analysis study is available for download [HERE]; and now features OnBioIPO and OnBioM&A data too!

The 2Q10 OnBioVC Trend Analysis tracked, in aggregate, 81 biopharma, diagnostic, device, medical-IT and biofuel venture financings totaling $1,664.2M. Compared to 1Q10 OnBioVC data, this investment activity represents an increase in the number of quarter-versus-quarter financings by 7 (81 v. 74) and an increase in quarter-versus-quarter invested capital of $404.1M ($1,664.2M v. $1,260.0M).

Many thanks to our wonderful partners who make OnBioVC possible. Please show them your support!

Apredica - Preclinical ADME Tox Contract Research
BioWest - The Rocky Mountain Region’s Premiere Device & Biotech Conference
Denson Group - Executive Search Working Exclusively in Med Device Manufacturing
Colorado Bioscience Association - Advocacy. Representation. Service.
San Jose BioCenter - Giving emerging companies that Big Company Advantage…

Faegre & Benson – Effective legal representation

Headwaters | MB – Independent middle market investment bank

DitchmanWest – National life science commercial real estate advisory

Freestone Group - Integrated Solutions for Emerging Life Science
Lockton - Lifescience Industry Specific Insurance Needs
Regulus - A Full Spectrum of Regulatory Affairs and Quality Assurance Solutions
BioBeers - Where Great Minds Drink Alike…

________________________________________________________________________

Sign up [HERE] for FREE Subscriptions to ‘Pharmaceutical Executive’ and ‘Life Science Leader’ Magazines (and other journals too!)